Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside
The DOI matches its Crossref record; 144 of the 147 references it cites were found in a registry or an index.
Abstract
Characterization of mice with cell-specific deletion or overexpression of the mineralocorticoid receptor (MR) shed a new light on its role in health and disease. Pathophysiological MR activation contributes to a plethora of deleterious molecular mechanisms in the development of cardiorenal diseases like chronic kidney disease (CKD) and heart failure (HF). Accordingly, the available steroidal MR antagonists (MRAs) spironolactone (first generation MRA) and eplerenone (second generation MRA) have been shown to be effective in reducing cardiovascular (CV) mortality and morbidity in patients with chronic HF and a reduced left ventricular ejection fraction (HFrEF). However, they remain underutilized, in large part owing to the risk inducing severe adverse events including hyperkalemia and worsening of kidney function, particularly when given on top of inhibitors of the renin angiotensin system (RAS) to patients with concomitant kidney dysfunction. Novel, potent, and selective non-steroidal MRAs (third generation) were identified in drug discovery campaigns and a few entered clinical development recently. One of these is finerenone with different physicochemical, pharmacokinetics, and pharmacological properties in comparison with the steroidal MRAs. Available data from five clinical phase II trials with finerenone in more than 2,000 patients with HF and additional CKD and/or diabetes as well as in patients with diabetic kidney disease demonstrated that neither hyperkalemia nor reductions in kidney function were limiting factors to its use. Moreover, finerenone demonstrated a nominally improved outcome compared to eplerenone in a phase IIb trial with 1,066 patients with HFrEF and concomitant type 2 diabetes mellitus (T2DM) and/or CKD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Finerenone is a novel, selective, nonsteroidal MR antagonist (MRA) that blocks MR-mediated sodium reabsorption and MR overactivation and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical kidney and cardiovascular disease models.8 , 9”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [9]
In the citing paper
“As a nonsteroidal, selective mineralocorticoid receptor antagonist, finerenone has been shown to have potent anti-inflammatory and antifibrotic effects while reducing the urinary albumin-to-creatinine ratio, which may be related to its benefits in renal outcome and HHF [67–70].”
In the citing paper
“As a nonsteroidal, selective mineralocorticoid receptor antagonist, finerenone has been shown to have potent anti-inflammatory and antifibrotic effects while reducing the urinary albumin-to-creatinine ratio, which may be related to its benefits in renal outcome and HHF [67–70].”
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citation2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Self-citationTrends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction
Owan, T. E., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052256 · Cited by 4,191
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8807 · Cited by 3,304
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationTHE GENERAL ADAPTATION SYNDROME AND THE DISEASES OF ADAPTATION1
SELYE, H. (1946) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-6-2-117 · Cited by 2,287
Arriza, J. L., Weinberger, C., Cerelli, G., Glaser, T. M., Handelin, B. L., Housman, D. E., & Evans, R. M. (1987) · Science · doi:10.1126/science.3037703 · Cited by 1,946
Clinical epidemiology of heart failure
Mosterd, A., & Hoes, A. W. (2007) · Heart · doi:10.1136/hrt.2003.025270 · Cited by 1,922
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study
Juurlink, D. N., Mamdani, M. M., Lee, D. S., Kopp, A., Austin, P. C., Laupacis, A., & Redelmeier, D. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040135 · Cited by 1,761
Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated
Funder, J. W., Pearce, P. T., Smith, R., & Smith, A. I. (1988) · Science · doi:10.1126/science.2845584 · Cited by 1,628
Cleland, J. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00823-0 · Cited by 1,549
Swedberg, K., Eneroth, P., Kjekshus, J., & Wilhelmsen, L. (1990) · Circulation · doi:10.1161/01.cir.82.5.1730 · Cited by 1,153
Molecular Determinants for the Tissue Specificity of SERMs
Shang, Y., & Brown, M. (2002) · Science · doi:10.1126/science.1068537 · Cited by 1,146
Edwards, C. R. W., Burt, D., Mcintyre, M. A., De Kloet, E. R., Stewart, P. M., Brett, L., Sutanto, W. S., & Monder, C. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90742-8 · Cited by 1,068
Pfeffer, M. A., Claggett, B., Assmann, S. F., Boineau, R., Anand, I. S., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., Gordeev, I., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013255 · Cited by 1,065
Self-citationZannad, F., Alla, F., Dousset, B., Perez, A., & Pitt, B. (2000) · Circulation · doi:10.1161/01.cir.102.22.2700 · Cited by 947
Self-citationYancy, C. W., Lopatin, M., Stevenson, L. W., De Marco, T., & Fonarow, G. C. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.09.022 · Cited by 927
Maggioni, A. P., Dahlström, U., Filippatos, G., Chioncel, O., Leiro, M. C., Drozdz, J., Fruhwald, F., Gullestad, L., Logeart, D., Fabbri, G., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft050 · Cited by 806
Self-citationANTI-ESCHERICHIA COLI ALPHA-HAEMOLYSIN IN CONTROL AND PATIENT SERA
Emody, L., Batai, I., Kerényi, M., Székely, J., & Polyak, L. (1982) · The Lancet · doi:10.1016/s0140-6736(82)90183-0 · Cited by 800
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Circulation · doi:10.1161/01.cir.0000139860.33974.28 · Cited by 750
Bakris, G. L., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., et al. (2015) · JAMA · doi:10.1001/jama.2015.10081 · Cited by 708
Self-citationActivating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy
Geller, D. S., Farhi, A., Pinkerton, N., Fradley, M., Moritz, M., Spitzer, A., Meinke, G., Tsai, F. T. F., Sigler, P. B., & Lifton, R. P. (2000) · Science · doi:10.1126/science.289.5476.119 · Cited by 675
Remodeling of the rat right and left ventricles in experimental hypertension.
Brilla, C. G., Pick, R., Tan, L. B., Janicki, J. S., & Weber, K. T. (1990) · Circulation Research · doi:10.1161/01.res.67.6.1355 · Cited by 674
Aldosterone induces a vascular inflammatory phenotype in the rat heart
Rocha, R., Rudolph, A. E., Frierdich, G. E., Nachowiak, D. A., Kekec, B. K., Blomme, E. A. G., McMahon, E. G., & Delyani, J. A. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01096.2001 · Cited by 655
Pitt, B., Kober, L., Ponikowski, P., Gheorghiade, M., Filippatos, G., Krum, H., Nowack, C., Kolkhof, P., Kim, S.-Y., & Zannad, F. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht187 · Cited by 591
Self-citationMcCullough, P. A., Philbin, E. F., Spertus, J. A., Kaatz, S., Sandberg, K. R., & Weaver, W. D. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01700-4 · Cited by 545
Filippatos, G., Anker, S. D., Böhm, M., Gheorghiade, M., Køber, L., Krum, H., Maggioni, A. P., Ponikowski, P., Voors, A. A., Zannad, F., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw132 · Cited by 446
Self-citationTribouilloy, C., Rusinaru, D., Mahjoub, H., Souliere, V., Levy, F., Peltier, M., Slama, M., & Massy, Z. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehm554 · Cited by 441
Kolkhof, P., Delbeck, M., Kretschmer, A., Steinke, W., Hartmann, E., Bärfacker, L., Eitner, F., Albrecht-Küpper, B., & Schäfer, S. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000091 · Cited by 430
Self-citationO'Connor, C. M., Abraham, W. T., Albert, N. M., Clare, R., Gattis Stough, W., Gheorghiade, M., Greenberg, B. H., Yancy, C. W., Young, J. B., & Fonarow, G. C. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.04.030 · Cited by 430
Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension
Weinberger, M. H., Roniker, B., Krause, S. L., & Weiss, R. J. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(02)02957-6 · Cited by 388
Usher, M. G., Duan, S. Z., Ivaschenko, C. Y., Frieler, R. A., Berger, S., Schütz, G., Lumeng, C. N., & Mortensen, R. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41080 · Cited by 383
Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro.
de Gasparo, M., Joss, U., Ramjoué, H. P., Whitebread, S. E., Haenni, H., Schenkel, L., Kraehenbuehl, C., Biollaz, M., Grob, J., & Schmidlin, J. (1987) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22580-0 · Cited by 343
Rise in plasma concentration of aldosterone during long-term angiotensin II suppression
STAESSEN, J., LIJNEN, P., FAGARD, R., VERSCHUEREN, L. J., & AMERY, A. (1981) · Journal of Endocrinology · doi:10.1677/joe.0.0910457 · Cited by 339
Mechanisms of Mineralocorticoid Action
Fuller, P. J., & Young, M. J. (2005) · Hypertension · doi:10.1161/01.hyp.0000193502.77417.17 · Cited by 329
Jaisser, F., & Farman, N. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011106 · Cited by 327
Self-citationImmunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor.
Lombès, M., Oblin, M. E., Gasc, J. M., Baulieu, E. E., Farman, N., & Bonvalet, J. P. (1992) · Circulation Research · doi:10.1161/01.res.71.3.503 · Cited by 309
Rickard, A. J., Morgan, J., Tesch, G., Funder, J. W., Fuller, P. J., & Young, M. J. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.131110 · Cited by 303
Güder, G., Bauersachs, J., Frantz, S., Weismann, D., Allolio, B., Ertl, G., Angermann, C. E., & Störk, S. (2007) · Circulation · doi:10.1161/circulationaha.106.653964 · Cited by 292
Rouleau, J.-L., Packer, M., Moyé, L., de Champlain, J., Bichet, D., Klein, M., Rouleau, J. R., Sussex, B., Arnold, J. M., Sestier, F., et al. (1994) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)90001-9 · Cited by 285
Parthasarathy, H. K., Ménard, J., White, W. B., Young, W. F., Williams, G. H., Williams, B., Ruilope, L. M., McInnes, G. T., Connell, J. M., & MacDonald, T. M. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283455ca5 · Cited by 281
Desai, A. S., Lewis, E. F., Li, R., Solomon, S. D., Assmann, S. F., Boineau, R., Clausell, N., Diaz, R., Fleg, J. L., Gordeev, I., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.09.007 · Cited by 274
Self-citationConditional Mineralocorticoid Receptor Expression in the Heart Leads to Life-Threatening Arrhythmias
Ouvrard-Pascaud, A., Sainte-Marie, Y., Bénitah, J.-P., Perrier, R., Soukaseum, C., Cat, A. N. D., Royer, A., Le Quang, K., Charpentier, F., Demolombe, S., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.503706 · Cited by 272
Self-citationDesign of selective nuclear receptor modulators: RAR and RXR as a case study
de Lera, A. R., Bourguet, W., Altucci, L., & Gronemeyer, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2398 · Cited by 270
Bärfacker, L., Kuhl, A., Hillisch, A., Grosser, R., Figueroa‐Pérez, S., Heckroth, H., Nitsche, A., Ergüden, J., Gielen‐Haertwig, H., Schlemmer, K., et al. (2012) · ChemMedChem · doi:10.1002/cmdc.201200081 · Cited by 270
Self-citationINHIBITION OF THE SODIUM-RETAINING INFLUENCE OF ALDOSTERONE BY PROGESTERONE*†
LANDAU, R. L., & LUGIBIHL, K. (1958) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-18-11-1237 · Cited by 262
Bauersachs, J., Jaisser, F., & Toto, R. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.04488 · Cited by 257
Self-citationAction of New Steroids in Blocking Effects of Aldosterone and Deoxycorticosterone on Salt
Kagawa, C. M., Cella, J. A., & Van Arman, C. G. (1957) · Science · doi:10.1126/science.126.3281.1015 · Cited by 256
Fraccarollo, D., Berger, S., Galuppo, P., Kneitz, S., Hein, L., Schütz, G., Frantz, S., Ertl, G., & Bauersachs, J. (2011) · Circulation · doi:10.1161/circulationaha.110.983023 · Cited by 226
Nagata, K., Obata, K., Xu, J., Ichihara, S., Noda, A., Kimata, H., Kato, T., Izawa, H., Murohara, T., & Yokota, M. (2006) · Hypertension · doi:10.1161/01.hyp.0000203772.78696.67 · Cited by 223
Konstitution des Aldosterons, des neuen Mineralocorticoids
Simpson, S. A., Tait, J. F., Wettstein, A., Neher, R., v. Euw, J., Schindler, O., & Reichstein, T. (1954) · Experientia · doi:10.1007/bf02158515 · Cited by 206
Amazit, L., Le Billan, F., Kolkhof, P., Lamribet, K., Viengchareun, S., Fay, M. R., Khan, J. A., Hillisch, A., Lombès, M., Rafestin-Oblin, M.-E., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.657957 · Cited by 196
Self-citationSica, D. A. (2005) · Heart Failure Reviews · doi:10.1007/s10741-005-2345-1 · Cited by 192
A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule
Fagart, J., Hillisch, A., Huyet, J., Bärfacker, L., Fay, M., Pleiss, U., Pook, E., Schäfer, S., Rafestin-Oblin, M.-E., & Kolkhof, P. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.131342 · Cited by 191
Self-citationThe evolution of aldosterone antagonists
Garthwaite, S. M., & McMahon, E. G. (2004) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.10.005 · Cited by 189
THE METABOLIC EFFECTS OF PROGESTERONE IN MAN*†
LANDAU, R. L., BERGENSTAL, D. M., LUGIBIHL, K., & KASCHT, M. (1955) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-15-10-1194 · Cited by 189
Zannad, F., Gattis Stough, W., Rossignol, P., Bauersachs, J., McMurray, J. J. V., Swedberg, K., Struthers, A. D., Voors, A. A., Ruilope, L. M., Bakris, G. L., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs257 · Cited by 178
Self-citationMolecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics
Kolkhof, P., & Borden, S. A. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.06.025 · Cited by 171
Self-citationThe endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure
Cat, A. N. D., Griol‐Charhbili, V., Loufrani, L., Labat, C., Benjamin, L., Farman, N., Lacolley, P., Henrion, D., & Jaisser, F. (2010) · The FASEB Journal · doi:10.1096/fj.09-147926 · Cited by 161
Self-citationReconsidering the Roles of the Mineralocorticoid Receptor
Funder, J. W. (2009) · Hypertension · doi:10.1161/hypertensionaha.108.119966 · Cited by 159
Bokma, J. P., Winter, M. M., Oosterhof, T., Vliegen, H. W., van Dijk, A. P., Hazekamp, M. G., Koolbergen, D. R., Groenink, M., Mulder, B. J., & Bouma, B. J. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv550 · Cited by 152
Lother, A., Berger, S., Gilsbach, R., Rösner, S., Ecke, A., Barreto, F., Bauersachs, J. K., Schütz, G., & Hein, L. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.163287 · Cited by 152
Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease
Bertocchio, J., Warnock, D. G., & Jaisser, F. (2011) · Kidney International · doi:10.1038/ki.2011.48 · Cited by 151
Self-citationTHE PRODUCTION OF CARDIAC LESIONS BY REPEATED INJECTIONS OF DESOXYCORTICOSTERONE ACETATE 123
Darrow, D. C., & Miller, H. C. (1942) · Journal of Clinical Investigation · doi:10.1172/jci101338 · Cited by 146
The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism
Marzolla, V., Armani, A., Zennaro, M., Cinti, F., Mammi, C., Fabbri, A., Rosano, G. M. C., & Caprio, M. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.011 · Cited by 143
Rickard, A. J., Morgan, J., Chrissobolis, S., Miller, A. A., Sobey, C. G., & Young, M. J. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.01803 · Cited by 143
Funder, J. W. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2004.12.010 · Cited by 137
Jia, G., Habibi, J., DeMarco, V. G., Martinez-Lemus, L. A., Ma, L., Whaley-Connell, A. T., Aroor, A. R., Domeier, T. L., Zhu, Y., Meininger, G. A., et al. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.06015 · Cited by 137
The Mineralocorticoid Receptor Promotes Fibrotic Remodeling in Atrial Fibrillation
Lavall, D., Selzer, C., Schuster, P., Lenski, M., Adam, O., Schäfers, H.-J., Böhm, M., & Laufs, U. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.519256 · Cited by 133
Nonsteroidal antagonists of the mineralocorticoid receptor
Kolkhof, P., Nowack, C., & Eitner, F. (2015) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000147 · Cited by 129
Self-citationBienvenu, L. A., Morgan, J., Rickard, A. J., Tesch, G. H., Cranston, G. A., Fletcher, E. K., Delbridge, L. M. D., & Young, M. J. (2012) · Endocrinology · doi:10.1210/en.2011-2098 · Cited by 128
Dietz, J. D., Du, S., Bolten, C. W., Payne, M. A., Xia, C., Blinn, J. R., Funder, J. W., & Hu, X. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.103580 · Cited by 126
Rickard, A. J., Morgan, J., Bienvenu, L. A., Fletcher, E. K., Cranston, G. A., Shen, J., Reichelt, M. E., Delbridge, L. M. D., & Young, M. J. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.203158 · Cited by 123
Svensson, M., Gustafsson, F., Galatius, S., Hildebrandt, P. R., & Atar, D. (2004) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2003.10.012 · Cited by 120
THE EFFECT OF SEX HORMONES ON THE RENAL EXCRETION OF ELECTROLYTES
Thorn, G. W., & Engel, L. L. (1938) · Journal of Experimental Medicine · doi:10.1084/jem.68.3.299 · Cited by 120
Carr, A. A., Kowey, P. R., Devereux, R. B., Brenner, B. M., Dahlöf, B., Ibsen, H., Lindholm, L. H., Lyle, P. A., Snapinn, S. M., Zhang, Z., et al. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.07.061 · Cited by 117
Rogerson, F. M., & Fuller, P. J. (2000) · Steroids · doi:10.1016/s0039-128x(99)00087-2 · Cited by 115
Mineralocorticoid binding in cultured smooth muscle cells and fibroblasts from rat aorta
Meyer, W. J., & Nichols, N. R. (1981) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(81)90046-7 · Cited by 113
PHARMACOKINETICS AND METABOLISM OF [14C]EPLERENONE AFTER ORAL ADMINISTRATION TO HUMANS
Cook, C. S., Berry, L., Bible, R. H., Hribar, J. D., Hajdu, E., & Liu, N. W. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.11.1448 · Cited by 107
Is aldosterone bad for the heart?
Funder, J. W. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.03.006 · Cited by 106
Tarjus, A., Martínez‐Martínez, E., Amador, C. A., Latouche, C., Moghrabi, S. E., Berger, T., Mak, T. W., Fay, R., Farman, N., Rossignol, P., et al. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.05431 · Cited by 105
Self-citationReichstein, T., & Euw, J. V. (1938) · Helvetica Chimica Acta · doi:10.1002/hlca.193802101149 · Cited by 103
Gómez, A. M., Rueda, A., Sainte-Marie, Y., Pereira, L., Zissimopoulos, S., Zhu, X., Schaub, R., Perrier, E., Perrier, R., Latouche, C., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.805804 · Cited by 103
Self-citationGrune, J., Benz, V., Brix, S., Salatzki, J., Blumrich, A., Hoeft, B., Klopfleisch, R., Foryst‐Ludwig, A., Kolkhof, P., & Kintscher, U. (2016) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000366 · Cited by 103
Self-citationSpironolactone: Disposition, Metabolism, Pharmacodynamics, and Bioavailability
Karim, A. (1978) · Drug Metabolism Reviews · doi:10.3109/03602537808993782 · Cited by 102
Gueret, A., Harouki, N., Favre, J., Galmiche, G., Nicol, L., Henry, J., Besnier, M., Thuillez, C., Richard, V. J., Kolkhof, P., et al. (2016) · Hypertension · doi:10.1161/hypertensionaha.115.06709 · Cited by 102
Self-citationMeyers, M. J., Arhancet, G. B., Hockerman, S. L., Chen, X., Long, S. A., Mahoney, M. W., Rico, J. R., Garland, D. J., Blinn, J. R., Collins, J. T., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100505n · Cited by 97
Pitt, B., Anker, S. D., Böhm, M., Gheorghiade, M., Køber, L., Krum, H., Maggioni, A. P., Ponikowski, P., Voors, A. A., Zannad, F., et al. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.218 · Cited by 92
Self-citationLiu, L. C. Y., Schutte, E., Gansevoort, R. T., van der Meer, P., & Voors, A. A. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1059819 · Cited by 91
Mavrakanas, T. A., Gariani, K., & Martin, P. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.11.007 · Cited by 91
Pitt, B., Filippatos, G., Gheorghiade, M., Kober, L., Krum, H., Ponikowski, P., Nowack, C., Kolkhof, P., Kim, S.-Y., & Zannad, F. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs061 · Cited by 90
Self-citationCicoira, M., Zanolla, L., Franceschini, L., Rossi, A., Golia, G., Zeni, P., Caruso, B., & Zardini, P. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02261-5 · Cited by 88
Nuclear Receptors in Bone Physiology and Diseases
Imai, Y., Youn, M.-Y., Inoue, K., Takada, I., Kouzmenko, A., & Kato, S. (2013) · Physiological Reviews · doi:10.1152/physrev.00008.2012 · Cited by 88
Buglioni, A., Cannone, V., Cataliotti, A., Sangaralingham, S. J., Heublein, D. M., Scott, C. G., Bailey, K. R., Rodeheffer, R. J., Dessì-Fulgheri, P., Sarzani, R., et al. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.03936 · Cited by 85
Sato, N., Ajioka, M., Yamada, T., Kato, M., Myoishi, M., Yamada, T., Kim, S.-Y., Nowack, C., Kolkhof, P., Shiga, T., et al. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-0122 · Cited by 77
Self-citationMineralocorticoid receptor‐mediated DNA damage in kidneys of DOCA‐salt hypertensive rats
Schupp, N., Kolkhof, P., Queisser, N., Gärtner, S., Schmid, U., Kretschmer, A., Hartmann, E., Oli, R. G., Schäfer, S., & Stopper, H. (2010) · The FASEB Journal · doi:10.1096/fj.10-173286 · Cited by 76
Self-citationSpironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites
Sungaila, I., Bartle, W. R., Walker, S. E., DeAngelis, C., Uetrecht, J., Pappas, C., & Vidins, E. I. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91730-r · Cited by 74
Heinig, R., Kimmeskamp‐Kirschbaum, N., Halabi, A., & Lentini, S. (2016) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.263 · Cited by 70
Mineralocorticoid receptor antagonists—pharmacodynamics and pharmacokinetic differences
Yang, J., & Young, M. J. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.02.005 · Cited by 68
Myeloid Mineralocorticoid Receptor Activation Contributes to Progressive Kidney Disease
Huang, L. L., Nikolic-Paterson, D. J., Han, Y., Ozols, E., Ma, F. Y., Young, M. J., & Tesch, G. H. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012111094 · Cited by 67
Barrera‐Chimal, J., Prince, S., Fadel, F., Moghrabi, S. E., Warnock, D. G., Kolkhof, P., & Jaisser, F. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014121216 · Cited by 65
Self-citationThorn, G. W., Howard, R. P., & Emerson, K. (1939) · Journal of Clinical Investigation · doi:10.1172/jci101060 · Cited by 65
Lentini, S., Heinig, R., Kimmeskamp‐Kirschbaum, N., & Wensing, G. (2016) · Fundamental & Clinical Pharmacology · doi:10.1111/fcp.12170 · Cited by 63
Favre, J., Gao, J., Zhang, A. D., Rémy‐Jouet, I., Ouvrard‐Pascaud, A., Dautréaux, B., Escoubet, B., Thuillez, C., Jaisser, F., & Richard, V. J. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00552.2010 · Cited by 62
Self-citationMineralocorticoids in the Heart and Vasculature: New Insights for Old Hormones
Lother, A., Moser, M., Bode, C., Feldman, R. D., & Hein, L. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124302 · Cited by 62
Aldosterone: A risk factor for vascular disease
Neves, M. F., & Schiffrin, E. L. (2003) · Current Hypertension Reports · doi:10.1007/s11906-003-0012-2 · Cited by 60
Production of Nephrosclerosis by Overdosage with Desoxycorticosterone Acetate.
Selye, H. (1942) · PubMed · Cited by 57
Lother, A., Fürst, D., Bergemann, S., Gilsbach, R., Grahammer, F., Huber, T. B., Hilgendorf, I., Bode, C., Moser, M., & Hein, L. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.06530 · Cited by 55
Orena, S., Maurer, T. S., She, L., Eudy, R., Bernardo, V., Dash, D., Loria, P., Banker, M. E., Tugnait, M., Okerberg, C. V., et al. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00115 · Cited by 54
Non-genomic actions of aldosterone: role in hypertension
Funder, J. W. (2001) · Current Opinion in Nephrology and Hypertension · doi:10.1097/00041552-200103000-00011 · Cited by 53
Aldosterone increases plasminogen activator inhibitor-1 synthesis in rat cardiomyocytes
Chun, T.-Y., & Pratt, J. H. (2005) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2005.03.016 · Cited by 52
Li, C., Zhang, Y. Y., Frieler, R. A., Xiao, Z., Zhang, W. C., Sun, X., Yang, Q. Z., Min, S., Huang, B., Berger, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110950 · Cited by 51
Weir, R. A. P., Tsorlalis, I. K., Steedman, T., Dargie, H. J., Fraser, R., McMurray, J. J. V., & Connell, J. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfr129 · Cited by 51
Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes
Albaghdadi, M. S., Gheorghiade, M., & Pitt, B. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr170 · Cited by 50
Self-citationDiscovery of Novel Cyanodihydropyridines as Potent Mineralocorticoid Receptor Antagonists
Arhancet, G. B., Woodard, S. S., Iyanar, K., Case, B. L., Woerndle, R. S., Dietz, J. D., Garland, D. J., Collins, J. T., Payne, M., Blinn, J. R., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100506y · Cited by 50
Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril
Johnson, E. S., Weinstein, J. R., Thorp, M. L., Platt, R. W., Petrik, A. F., Yang, X., Anderson, S., & Smith, D. H. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1923 · Cited by 46
Roush, G. C., Ernst, M. E., Kostis, J. B., Yeasmin, S., & Sica, D. A. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000000762 · Cited by 45
Ruilope, L. M., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., et al. (2014) · American Journal of Nephrology · doi:10.1159/000371497 · Cited by 41
Self-citationArhancet, G. B., Woodard, S. S., Dietz, J. D., Garland, D. J., Wagner, G. M., Iyanar, K., Collins, J. T., Blinn, J. R., Numann, R. E., Hu, X., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1002827 · Cited by 40
Anticortisol Action of Aldosterone
Selye, H. (1955) · Science · doi:10.1126/science.121.3141.368 · Cited by 37
Aldosterone increases osteopontin gene expression in rat endothelial cells
Sugiyama, T., Yoshimoto, T., Hirono, Y., Suzuki, N., Sakurada, M., Tsuchiya, K., Minami, I., Iwashima, F., Sakai, H., Tateno, T., et al. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.056 · Cited by 37
Kosaka, H., Hirayama, K., Yoda, N., Sasaki, K., Kitayama, T., Kusaka, H., & Matsubara, M. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.03.018 · Cited by 37
Comparison of Agents That Affect Aldosterone Action
Tamargo, J. L., Solini, A., & Ruilope, L. M. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.04.005 · Cited by 34
Matsui, T., Takeuchi, M., & Yamagishi, S. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.04.149 · Cited by 33
Mineralocorticoid Receptor Antagonists for the Treatment of Hypertension and Diabetic Nephropathy
Piotrowski, D. W. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300806c · Cited by 33
Aldosterone Blockade in CKD: Emphasis on Pharmacology
Schwenk, M. H., Hirsch, J. S., & Bomback, A. S. (2015) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.08.003 · Cited by 32
Gynecomastia During Therapy with Spironolactone
Mann, N. M. (1963) · JAMA · doi:10.1001/jama.1963.73700230005018 · Cited by 31
Dinsdale, C., Wani, M., Steward, J., & O'Mahony, M. S. (2005) · Age and Ageing · doi:10.1093/ageing/afi104 · Cited by 29
Bienvenu, L. A., Reichelt, M. E., Morgan, J., Fletcher, E. K., Bell, J. R., Rickard, A. J., Delbridge, L. M. D., & Young, M. J. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.05981 · Cited by 28
Yu, L., Helms, M. N., Yue, Q., & Eaton, D. C. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00605.2007 · Cited by 27
Mineralocorticoid-receptor blockade, hypertension and heart failure
Funder, J. W. (2005) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0016 · Cited by 22
Enzymes and receptors: Challenges and future directions
Funder, J. W. (1994) · Steroids · doi:10.1016/0039-128x(94)90096-5 · Cited by 19
Ma, F. Y., Han, Y., Nikolic‐Paterson, D. J., Kolkhof, P., & Tesch, G. H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145666 · Cited by 18
Self-citationMineralocorticoid receptor modulators: a patent review (2007 – 2012)
Collin, M., Niemann, F., & Jaisser, F. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.854772 · Cited by 15
Self-citationBinding of Spirolactones to Human Plasma Proteins
Chien, Y. W., Hofmann, L. M., Lambert, H. J., & Tao, L. C. (1976) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600650919 · Cited by 14
Kim, H. Y., Bae, E. H., Kwon, S. S., & Kim, S. W. (2014) · Kidney & Blood Pressure Research · doi:10.1159/000368470 · Cited by 13
Self-citationEffects of Canrenone on Aorta and Right Ventricle of the Rat
Cargnelli, G., Trevisi, L., Debetto, P., Luciani, S., & Bova, S. (2001) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200105000-00006 · Cited by 13
[No mutations in Drosophila melanogaster due to 1-allyl-3,5-diethyl-6-chlorouracil (ACIU)].
Platt, D., & Pauli, H. H. (1972) · PubMed · Cited by 10
Research works printed but not linked: 5
- Ergueden JK, Kolkhof P, Sandner P, Kuhl A, Stasch JP, Pook E, Schlemmer KH (2005) Fluorenone 1, 4,-dihydropyridin derivatives, WO/2005/087740. Bayer Healthcare AG, Wuppertal
- Kolkhof P, Flamme I, Figueroa-Pérez S, Baerfacker L, Hartmann E, Rinke M, Schäfer S (2006) Cardiac and renal protection by a new mineralocorticoid receptor antagonist in salt-sensitive hypertension [abstract P754]. Eur Heart J 27(Suppl 1):110
- Mulder P, BarreraChimal J, El Moghrabi S, Kolkhof P, Ouvrard-Pascaud A, Jaisser F (2016) Finerenone improves diastolic function in a preclinical model of type2 diabetes mellitus. Eur Heart J 37(Abstract Supplement):829
- Platt D, Pauli H (1972) Studies on organ- and subcellular distribution of [3H]spironolactone in animals [in German]. Arzneimittelforschung 22:1801–1802
- Simpson SA, Tait JF (1953) Memoirs of the Society for Endocrinology, No. 2. The determination of adrenal cortical steroids and their metabolites. Dennis Dobson, Ltd., London, p 9
Cited by
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationAgarwal, R., Filippatos, G., Pitt, B., Anker, S. D., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Gebel, M., Ruilope, L. M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab777 · Cited by 1,317
“Finerenone is a novel, selective, nonsteroidal MR antagonist (MRA) that blocks MRmediated sodium reabsorption and MR overactivation and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical kidney and cardiovascular disease models.(8,9) The FInerenone in reducing kiDnEy faiLure and dIsease prOgre…”
Self-citationMolecular mechanisms and therapeutic targets for diabetic kidney disease
Tuttle, K. R., Agarwal, R., Alpers, C. E., Bakris, G. L., Brosius, F. C., Kolkhof, P., & Uribarri, J. (2022) · Kidney International · doi:10.1016/j.kint.2022.05.012 · Cited by 668
Self-citationSteroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Agarwal, R., Kolkhof, P., Bakris, G., Bauersachs, J., Haller, H., Wada, T., & Zannad, F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa736 · Cited by 638
Self-citation
Metadata
- Authors
- Kolkhof, P., Jaisser, F., Kim, S.-Y., Filippatos, G., Nowack, C., & Pitt, B.
- Affiliations
- Bayer (Germany) (DE)
- National and Kapodistrian University of Athens (GR)
- University of Michigan (US)
- Corresponding author
- Kolkhof, Peter
- Venue
- Handbook of Experimental Pharmacology
- Publisher
- Springer International Publishing
- Published
- 2016
- Volume
- 243
- Pages
- 271-305
- ISSN
- 0171-2004 (ISSN-L)
- 1865-0325
- OpenAlex
- W2555239285
- Cited by
- 180
- References
- 147
- Citations by year
- 2026: 22 · 2025: 25 · 2024: 22 · 2023: 23 · 2022: 28 · 2021: 20 · 2020: 16 · 2019: 14 · 2018: 6 · 2017: 3 · 2016: 1
- FWCI
- 33.76
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Handbook of experimental pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- mineralocorticoid receptor antagonists, finerenone, spironolactone, eplerenone, heart failure with reduced ejection fraction, chronic kidney disease, cardiorenal disease, diabetic nephropathy, hyperkalemia, renin-angiotensin system inhibitors, type 2 diabetes, non-steroidal MRAs, drug safety and efficacy
- MeSH terms
- Eplerenone, Mineralocorticoid Receptor Antagonists, Animals, Diabetic Nephropathies, Fibroblasts, Heart Failure, Humans, Macrophages, Muscle, Smooth, Vascular, Naphthyridines, Spironolactone, Stroke Volume, Receptors, Mineralocorticoid, Myocytes, Cardiac, Myocytes, Smooth Muscle, Endothelial Cells, Cardio-Renal Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.